H5N1 Milk Detection Study
Part of paid clinical trials in Atlanta, Georgia.
- Sponsor
- Emory University
- Study ID
- NCT06850298
- Status
- Recruiting
Conditions
- Influenza
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 64 Years
- Healthy Volunteers
- Accepted
Interventions
- Pasteurized milk contaminated with killed A(H5) virus — OTHERMilk to be used in the study will be obtained from the CDC. Pasteurized commercial milk likely to contain detectable A(H5N1) particles will be obtained from a source such as a recently affected dairy farm. The CDC Influenza Division laboratory (Viral, Surveillance, and Diagnosis Branch) will test the milk to confirm the presence of viral A(H5) RNA using a protocol developed and validated by the US FDA Agricultural Research Service. The US Food and Drug Administration (FDA) has indicated that the consumption of commercial pasteurized dairy products in the US is safe.
Study Details
The purpose of this study is to determine whether drinking pasteurized milk (milk heated to kill harmful germs) that contains inactive particles of a flu virus called A(H5) could lead to the detection of the virus in the nose or throat. Inactive particles are not capable of causing disease. The results will help the Centers for Disease Control and Prevention (CDC) better understand how milk consumption could affect flu surveillance. Investigators also want to see if the body produces antibodies in response to this milk consumption.
Key Dates
- Start date
- May 9, 2025
- Status verified
- Apr 2026
- Primary completion
- Nov 30, 2026
- Completion
- Nov 30, 2026
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- BASIC_SCIENCE
Arms
- Experimental: 1-Day GroupParticipants will consume 250 mL of pasteurized commercial milk at a study visit.
- Experimental: 3-Day GroupParticipants will consume 250 mL of pasteurized commercial milk for a total of 3 daily consecutive visits.
Primary Outcome Measure
Proportion of respiratory specimens with influenza detected [ Time Frame: Up to 30 days after milk consumption ]
Central Contacts
- Daniel Graciaa, MD, MPH, MSc404-712-1370
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Hope Clinic | Atlanta | Georgia | 30322 | Daniel Graciaa, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Atlanta, GA
By research site
Related Studies
- Influenza Human Challenge ModelPHASE1 · Recruiting · Emory University · Atlanta, Georgia
- Bone Marrow and Peripheral Blood Immune Responses StudyPHASE4 · Recruiting · Emory University · Atlanta, Georgia
- High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) RecipientsPHASE2 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Stanford, California
- A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household ContactsPHASE3 · Recruiting · Hoffmann-La Roche · Birmingham, Alabama